M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Cell Therapeutics introduces PIXUVRI for treating adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, reflecting its first and only approved monotherapy in the EU for this patient population
Biopharmaceutical company Cell Therapeutics (NASDAQ)(MTA:CTIC) revealed on Tuesday the launch of PIXUVRI for the treatment of multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma at the 54th annual scientific meeting of the British Society for Haematology in the UK.
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives